Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Severe asthma and asthma-chronic obstructive pulmonary disease syndrome

We read the excellent work by Sally Wenzel and colleagues (July 2, p 31)1 with great interest. Treatment with dupilumab, a human anti-interleukin-4 receptor α monoclonal antibody, resulted in elevated forced expiratory volume in 1 s (FEV1), improved asthma symptom control, and reduced annual rates of exacerbation in patients with uncontrolled persistent asthma.